NovoCure Data Breach Reported to SEC: Details Limited

NovoCure, a global oncology and medical device company, has disclosed a data breach affecting some of its information systems.

NovoCure is a commercial-stage, publicly traded company best known for developing Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment that uses alternating electric fields to disrupt cancer cell division.

The company reported the incident to the U.S. Securities and Exchange Commission in a Form 8-K filing on Sept. 1, 2026.

NovoCure became aware of unauthorized access to some of its information systems in mid-August 2020.

The company's investigation into the incident determined that it resulted in the exposure of certain identifiable information. The specific types of personal information that were exposed were not detailed in the SEC filing. The filing provided limited details about the nature and scope of the data involved.

NovoCure's response to the breach

NovoCure stated its intentions to continue monitoring the situation as its investigation progresses. Anyone who believes they may have been affected by this incident may want to visit the company's official website or contact NovoCure directly for updated information.